Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3237-3243

  Marcelin, Anne Genevieve ^a,b   Masquelier, Bernard ^c   Descamps, Diane ^d,e   Izopet, Jacques ^f   Charpentier, Charlotte ^g   Alloui, Chakib ^h   Bouvier Alias, Magali ⁱ   Signori Schmuck, Anne ^j   Montes, Brigitte ^k   Chaix, Marie Laure ^l   Amiel, Corinne ^m   Dos Santos, Georges ⁿ   Ruffault, Annick ^o   Barin, Francis ^p   Peytavin, Gilles ^d   Lavignon, Marc ^q   Flandre, Philippe ^a,b   Calvez, Vincent ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k MONTPELLIER UNIVERSITY HOSPITAL   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m HÔPITAL TENON   (France)

ⁿ CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^o RENNES UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY HOSPITAL OF TOURS   (France)

^q BOEHRINGER INGELHEIM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PYRIDINES; PYRONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 50949126474     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00133-08     Document Type: Article

References (23)

1. Bacheler, L. T., H. Vermeiren, B. Winters, H. Van Der Borght, and D. Mayers. 2006. Abstr. 4th Eur. HIV Drug Resist. Workshop, abstr. 40.
2. Baxter, J. D., J. M. Schapiro, C. A. Boucher, V. M. Kohlbrenner, D. B. Hall, J. R. Scherer, and D. L. Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologie response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
3. Bonneau, P. R., Y. Lie, and R. Bethell. 2007. Abstr. 11th Eur. AIDS Conf., abstr. P3.3/02.
4. Cahn, P., J. Villacian, A. Lazzarin, C. Katlama, B. Grinsztejn, K. Arasteh, P. Lopez, N. Clumeck, J. Gerstoft, N. Stavrianeas, S. Moreno, F. Antunes, D. Neubacher, and D. Mayers. 2006. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin. Infect. Dis. 43:1347-1356.
5. Descamps, D., C. Delaugerre, B. Masquelier, A. Ruffault, A. G. Marcelin, J. Izopet, M. L. Chaix, V. Calvez, F. Brun-Vezinet, and D. Costagliola. 2006. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J. Med. Virol. 78:153-160.
6. Doyon, L., S. Tremblay, L. Bourgon, E. Wardrop, and M. G. Cordingley. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antivir. Res. 68:27-35.
7. Flandre, P., A. G. Marcelin, J. Pavie, N. Shmidely, M. Wirden, O. Lada, M. C. Bernard, J. M. Molina, and V. Calvez. 2005. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir. Ther. 10:479-487.
8. Flandre, P., A. G. Marcelin, V. Soriano, S. Yerly, C. Katlama, and V. Calvez. 2006. Abstr. XV Int. HIV Drug Resist. Workshop, abstr. 67.
9. Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
10. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
11. Larder, B. A., K. Hertogs, S. Bloor, C. H. van den Eynde, W. DeCian, Y. Wang, W. W. Freimuth, and G. Tarpley. 2000. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14:1943-1948.
12. Marcelin, A. G., P. Flandre, C. de Mendoza, B. Roquebert, G. Peytavin, L. Valer, M. Wirden, S. Abbas, C. Katlama, V. Soriano, and V. Calvez. 2007. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antivir. Ther. 12:247-252.
13. Marcelin, A. G., P. Flandre, J. Pavie, N. Schmidely, M. Wirden, O. Lada, D. Chiche, J. M. Molina, and V. Calvez. 2005. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother. 49:1739-1744.
14. Marcelin, A. G., B. Masquelier, D. Descamps, J. Izopet, C. Charpentier, C. Alloui, M. Bouvier-Alias, A. Signori-Schmuck, B. Montes, M.-L. Chaix, C. Amiel, G. Dos Santos, A. Ruffault, F. Barin, G. Peytavin, M. Lavignon, P. Flandre, and V. Calvez. 2007. Abstr. 14th Conf. Retrovir. Opportunistic Infect., abstr. 612.
15. Marcelin, A. G., B. Masquelier, D. Descamps, J. Izopet, C. Charpentier, C. Alloui, M. Bouvier-Alias, A. Signori-Schmuck, B. Montes, M.-L. Chaix, C. Amiel, G. Dos Santos, A. Ruffault, F. Barin, G. Peytavin, M. Lavignon, P. Flandre, and V. Calvez. 2007. Abstr. XVI Int. HIV Drug Resist. Workshop, abstr. 74.
16. Naeger, L. K., and K. A. Struble. 2007. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 21:179-185.
17. Parkin, N. T., and C. Chappey. 2006. Abstr. 13th Conf. Retrovir. Opportunistic Infect., abstr. 637.
18. Peytavin, G., A. G. Marcelin, A. Rouault, M. Bonmarchand, H. Ait-Mohand, B. Cassard, A. Simon, L. Schneider, D. Costagliola, V. Calvez, and C. Katlama. 2006. Abstr. 13th Conf. Retrovir. Opportunistic Infect., abstr. 591.
19. Poppe, S. M., D. E. Slade, K. T. Chong, R. R. Hinshaw, P. J. Pagano, M. Markowitz, D. D. Ho, H. Mo, R. R. Gorman III, T. J. Dueweke, S. Thaisrivongs, and W. G. Tarpley. 1997. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41:1058-1063.
20. Rusconi, S., S. La Seta Catamancio, P. Citterio, S. Kurtagic, M. Violin, C. Balotta, M. Moroni, M. Galli, and A. d'Arminio-Monforte. 2000. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. 44:1328-1332.
21. Scherer, J. R., C. A. Boucher, J. D. Baxter, J. M. Schapiro, V. Kohlbrenner, and D. B. Hall. 2007. Abstr. 11th Eur. HIV Drug Resist. Workshop, abstr. P3.4/07.
22. Scherer, J. R., V. Kohlbrenner, D. B. Hall, J. D. Baxter, J. M. Schapiro, and C. A. Boucher. 2007. Abstr. 5th Eur. HIV Drug Resist. Workshop, abstr. 100.
23. Vora, S., A. G. Marcelin, H. F. Gunthard, P. Flandre, H. H. Hirsch, B. Masquelier, A. Zinkernagel, G. Peytavin, V. Calvez, L. Perrin, and S. Yerly. 2006. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20:35-40.